Corey Davis

In a report published Tuesday, Jefferies analyst Corey Davis reiterated a Buy rating on AcelRx Pharmaceuticals (NASDAQ: ACRX), and raised the price target from $8.00 to $13.00. In the report, Jefferies noted, “We are making numerous model adjustments as we move closer to an NDA filing for ARX-...

In a report published Wednesday, Jefferies analyst Corey Davis reiterated a Buy rating on Forest Laboratories (NYSE: FRX), and raised the price target from $43.00 to $48.00. In the report, Jefferies noted, “In an effort to avert a 3rd proxy battle, FRX announced a new, Carl Icahn-designated...

In a report published Friday, Jefferies analyst Corey Davis reiterated a Buy rating on Endo Health Solutions (NASDAQ: ENDP), and raised the price target from $37.00 to $45.00. In the report, Jefferies noted, “ENDP CEO Rajiv DeSilva made his 1st public appearance at our conference today. Despite...

In a report published Tuesday, Jefferies analyst Corey Davis reiterated a Buy rating on Salix Pharmaceuticals (NASDAQ: SLXP), and raised the price target from $63.00 to $70.00. In the report, Jefferies noted, “Apriso for ulcerative colitis is SLXP's 2nd biggest drug. It's seen a marked boost...

In a report published Tuesday, Jefferies analyst Corey Davis reiterated a Hold rating on Actavis (NYSE: ACT), and raised the price target from $120.00 to $133.00. In the report, Jefferies noted, “ACT buying WCRX makes sense strategically and financially, but given the stock run subsequent to a...

Jefferies & Company analysts Corey Davis, Graig Suvannavejh and Oren G. Livnat maintained their Buy rating for shares of Endo Pharmaceuticals (NASDAQ: ENDP), with a price target of $26 per share. The analysts wrote that after announcing plans to acquire HealthTronics Inc. (NASDAQ: HTRN) for $...